OpenURL Connection Search

Select item for more details and to access through your institution.

Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
Published in:
American Journal of Hematology, 2023, v. 98, n. 9, p. E233, doi. 10.1002/ajh.27005
By:
- DiNardo, Courtney D.;
- De Botton, Stéphane;
- Pollyea, Daniel A.;
- Stone, Richard M.;
- Altman, Jessica K.;
- Fathi, Amir T.;
- Limsakun, Tharin;
- Liang, Min;
- Choe, Sung;
- Hossain, Mohammad;
- Tron, Adriana E.;
- Meng, Qian;
- Kapsalis, Stephanie M.;
- Pandya, Shuchi S.;
- Stein, Eytan M.
Publication type:
Article
MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S346, doi. 10.1016/S2152-2650(21)01805-X
By:
- DiNardo, Courtney D.;
- Foran, James M.;
- Watts, Justin M.;
- Stein, Eytan M.;
- de Botton, Stéphane;
- Fathi, Amir T.;
- Prince, Gabrielle T.;
- Stein, Anthony S.;
- Stone, Richard M.;
- Patel, Prapti A.;
- Roboz, Gail J.;
- Arellano, Martha L.;
- Erba, Harry P.;
- Pigneux, Arnaud;
- Stuart, Robert K.;
- Thomas, Xavier;
- Uy, Geoffrey L.;
- Lemieux, Ian R.;
- Zhang, Vickie;
- Kapsalis, Stephanie M.
Publication type:
Article
Poster: MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S230, doi. 10.1016/S2152-2650(21)01451-8
By:
- DiNardo, Courtney D.;
- Foran, James M.;
- Watts, Justin M.;
- Stein, Eytan M.;
- De Botton, Stéphane;
- Fathi, Amir T.;
- Prince, Gabrielle T.;
- Stein, Anthony S.;
- Stone, Richard M.;
- Patel, Prapti A.;
- Roboz, Gail J.;
- Arellano, Martha L.;
- Erba, Harry P.;
- Pigneux, Arnaud;
- Stuart, Robert K.;
- Thomas, Xavier;
- Uy, Geoffrey L.;
- Lemieux, Ian R.;
- Zhang, Vickie;
- Kapsalis, Stephanie M.
Publication type:
Article
Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML).
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S217, doi. 10.1016/j.clml.2019.07.090
By:
- DiNardo, Courtney D.;
- Stein, Anthony S.;
- Stein, Eytan M.;
- Fathi, Amir T.;
- Frankfurt, Olga;
- Schuh, Andre C.;
- Döhner, Hartmut;
- Martinelli, Giovanni;
- Raffoux, Emmanuel;
- Tan, Peter;
- Zeidan, Amer;
- de Botton, Stéphane;
- Kantarjian, Hagop M.;
- Stone, Richard M.;
- Lam, Du;
- Wang, Xiwei;
- Gong, Jing;
- Kapsalis, Stephanie M.;
- Hickman, Denice;
- Zhang, Vickie
Publication type:
Article

Found: 4

Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.

MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.

Poster: MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.

Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML).